FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3182107672> ?p ?o ?g. }

• W3182107672 endingPage "1274" @default.
• W3182107672 startingPage "1272" @default.
• W3182107672 abstract "Dear Editor, We report data on the antibody response against the SARS-CoV-2 receptor-binding domain (RBD) in healthcare professionals from two hospitals in Copenhagen at baseline and 3 weeks post the first injection with the BNT162b2 mRNA COVID-19 vaccine. The response was assessed using assays measuring antibody neutralizing capacity (NAbs) [1] and direct binding of IgG, IgM and IgA [2]. Moreover, we tested antibody responses against the nucleocapsid (N) protein, which is not a part of the vaccine and used as a proxy for natural infection. For more details, see the Supporting Information. Out of the 1460 participants, 1227 were females (Table S1). The included subjects were categorized as SARS-CoV-2 primed with a natural infection if they were positive at day 0 (baseline). At baseline, 108 participants (7.4%) and approximately 3 weeks after the first vaccination, 122 participants (8.3%) were N protein seropositive, respectively (Fisher's exact test, p < 0.0001). A total of 65 of the 108 (60.2%) seropositive patients had received reverse transcription polymerase chain reaction (RT-PCR) laboratory confirmation of SARS-CoV-2 infection before inclusion in the study. Divided according to age, seropositivity at baseline showed that the prevalence was highest among the participants below 30 years of age (17.3%) and decreased (3.9%) in those 60 years of age and above (Table S1; X2, p < 0.0001). Thirty participants (2.1%) remained IgG RBD seronegative after 3 weeks. In individuals with a previous SARS-CoV-2 infection compared with infection naïve, the vaccine responses were significantly increased for both NAbs, IgG, IgA and IgM (Mann–Whitney U test, p < 0.0001, p < 0.0001, p < 0.0001 and p = 0.0001, respectively; Fig. 1a–d). Among previously SARS-CoV-2 infected individuals, 98.4% were positive for NAbs compared with 75.8% in the infection naïve group 3 weeks post-vaccination (Mann–Whitney U test, p < 0.0001) (Fig. 1a). The vaccine antibody responses decreased gradually by increasing age (Kruskal–Wallis test, p < 0.0001) (Fig. 1e,f). Females had a higher neutralizing and IgG antibody vaccine response than males (Mann–Whitney U test, p = 0.0017 and 0.0085, respectively; Fig. 1g,h). No significant difference in vaccine responses was reflected in body mass index (BMI) nor in the time since the positive PCR test (Figs S1 and S2). Multiple regression analysis (Table S2) revealed that with increasing age, the IgG antibody response after the first vaccination declined significantly compared to the youngest age group (<30 years). Previous SARS-CoV-2 infection was associated with the most pronounced IgG antibody response (p < 0.0001). Male sex was associated with a lower IgG antibody response in all regression models (p = 0.0002, p < 0.0001 and p = 0.001). Furthermore, when dividing the participants into BMI groups, we found no significant association to IgG antibody responses (p > 0.05). This study shows that a single dose of the BNT162b2 vaccine induces a robust antibody response in individuals that have experienced previous COVID-19 infection. This is compatible with a recent observation that prior infection equals a double vaccine dose of the BNT162b2 [3]. In general, low responsiveness to vaccines increases with age, and our observation that the antibody responses to the BNT162b2 vaccine decrease by each centile are compatible with this knowledge [4]. Furthermore, sex appeared to play a significant but less pronounced role since females mounted a significantly higher antibody response, which has been reported previously regarding other viral vaccines [5]. Fourteen individuals (1.1%) became N protein-positive during the 3-week observation period, indicating that they had contracted COVID-19 after the first injection. This agrees with initial findings in the BNT162b2 phase three trial that there is a lag phase of around 10–14 days before a robust protective response is generated [6]. Thirty individuals (2.1%) of the vaccinated participants did not generate any vaccine antibody response against RBD. These individuals were also negative for N protein responses. Our results are in line with previous observations that about 2%–10% of healthy individuals fail to mount antibody responses to routine vaccines [7]. However, it might be possible that some individuals may need a second booster to mount a detectable immunological response. Obese individuals may have increased susceptibility to infections [7], and for some vaccines elevated BMI is associated with poor vaccine responsiveness [8, 9]. We did not find an association of vaccine responses with BMI in this cohort. However, this should be interpreted with some caution. The median BMI in our study was 23.9, and 90% of the included subjects had a BMI below 30 and were thus not obese. Therefore, our study might have been underpowered to detect an effect of obesity. We conclude that age and sex appear to be significant factors in how well a vaccine response is mounted. Previous natural SARS-CoV-2 infection is associated with a more rapid and robust response to a COVID-19 vaccine than individuals who were not infected. The authors declare to have no conflict of interest. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article." @default.
• W3182107672 created "2021-07-19" @default.
• W3182107672 creator A5001872521 @default.
• W3182107672 creator A5009149998 @default.
• W3182107672 creator A5012855725 @default.
• W3182107672 creator A5016630110 @default.
• W3182107672 creator A5016979638 @default.
• W3182107672 creator A5018114131 @default.
• W3182107672 creator A5027709751 @default.
• W3182107672 creator A5032262582 @default.
• W3182107672 creator A5045010627 @default.
• W3182107672 creator A5051619491 @default.
• W3182107672 creator A5055172908 @default.
• W3182107672 creator A5056032676 @default.
• W3182107672 creator A5060569928 @default.
• W3182107672 creator A5063231959 @default.
• W3182107672 creator A5079979177 @default.
• W3182107672 creator A5081108450 @default.
• W3182107672 creator A5082182829 @default.
• W3182107672 creator A5085037045 @default.
• W3182107672 creator A5087185637 @default.
• W3182107672 creator A5088476938 @default.
• W3182107672 date "2021-08-02" @default.
• W3182107672 modified "2023-10-06" @default.
• W3182107672 title "Antibody‐dependent neutralizing capacity of the SARS‐CoV‐2 vaccine BNT162b2 with and without previous COVID‐19 priming" @default.
• W3182107672 cites W2026161601 @default.
• W3182107672 cites W2122455470 @default.
• W3182107672 cites W2131643987 @default.
• W3182107672 cites W2296358134 @default.
• W3182107672 cites W3103127508 @default.
• W3182107672 cites W3111255098 @default.
• W3182107672 cites W3146894320 @default.
• W3182107672 cites W3186476690 @default.
• W3182107672 cites W4250020414 @default.
• W3182107672 doi "https://doi.org/10.1111/joim.13366" @default.
• W3182107672 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8447364" @default.
• W3182107672 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34237190" @default.
• W3182107672 hasPublicationYear "2021" @default.
• W3182107672 type Work @default.
• W3182107672 sameAs 3182107672 @default.
• W3182107672 citedByCount "14" @default.
• W3182107672 countsByYear W31821076722021 @default.
• W3182107672 countsByYear W31821076722022 @default.
• W3182107672 countsByYear W31821076722023 @default.
• W3182107672 crossrefType "journal-article" @default.
• W3182107672 hasAuthorship W3182107672A5001872521 @default.
• W3182107672 hasAuthorship W3182107672A5009149998 @default.
• W3182107672 hasAuthorship W3182107672A5012855725 @default.
• W3182107672 hasAuthorship W3182107672A5016630110 @default.
• W3182107672 hasAuthorship W3182107672A5016979638 @default.
• W3182107672 hasAuthorship W3182107672A5018114131 @default.
• W3182107672 hasAuthorship W3182107672A5027709751 @default.
• W3182107672 hasAuthorship W3182107672A5032262582 @default.
• W3182107672 hasAuthorship W3182107672A5045010627 @default.
• W3182107672 hasAuthorship W3182107672A5051619491 @default.
• W3182107672 hasAuthorship W3182107672A5055172908 @default.
• W3182107672 hasAuthorship W3182107672A5056032676 @default.
• W3182107672 hasAuthorship W3182107672A5060569928 @default.
• W3182107672 hasAuthorship W3182107672A5063231959 @default.
• W3182107672 hasAuthorship W3182107672A5079979177 @default.
• W3182107672 hasAuthorship W3182107672A5081108450 @default.
• W3182107672 hasAuthorship W3182107672A5082182829 @default.
• W3182107672 hasAuthorship W3182107672A5085037045 @default.
• W3182107672 hasAuthorship W3182107672A5087185637 @default.
• W3182107672 hasAuthorship W3182107672A5088476938 @default.
• W3182107672 hasBestOaLocation W31821076721 @default.
• W3182107672 hasConcept C126322002 @default.
• W3182107672 hasConcept C159654299 @default.
• W3182107672 hasConcept C203014093 @default.
• W3182107672 hasConcept C22070199 @default.
• W3182107672 hasConcept C2779134260 @default.
• W3182107672 hasConcept C2779261636 @default.
• W3182107672 hasConcept C3007834351 @default.
• W3182107672 hasConcept C3008058167 @default.
• W3182107672 hasConcept C3018913218 @default.
• W3182107672 hasConcept C524204448 @default.
• W3182107672 hasConcept C71924100 @default.
• W3182107672 hasConceptScore W3182107672C126322002 @default.
• W3182107672 hasConceptScore W3182107672C159654299 @default.
• W3182107672 hasConceptScore W3182107672C203014093 @default.
• W3182107672 hasConceptScore W3182107672C22070199 @default.
• W3182107672 hasConceptScore W3182107672C2779134260 @default.
• W3182107672 hasConceptScore W3182107672C2779261636 @default.
• W3182107672 hasConceptScore W3182107672C3007834351 @default.
• W3182107672 hasConceptScore W3182107672C3008058167 @default.
• W3182107672 hasConceptScore W3182107672C3018913218 @default.
• W3182107672 hasConceptScore W3182107672C524204448 @default.
• W3182107672 hasConceptScore W3182107672C71924100 @default.
• W3182107672 hasIssue "6" @default.
• W3182107672 hasLocation W31821076721 @default.
• W3182107672 hasLocation W31821076722 @default.
• W3182107672 hasOpenAccess W3182107672 @default.
• W3182107672 hasPrimaryLocation W31821076721 @default.
• W3182107672 hasRelatedWork W2041212420 @default.
• W3182107672 hasRelatedWork W3036305013 @default.
• W3182107672 hasRelatedWork W3048632145 @default.
• W3182107672 hasRelatedWork W3111431752 @default.
• W3182107672 hasRelatedWork W3173728808 @default.

• next